文献速递肺外科

围术期度伐利尤单抗联合新辅助化疗在不同手术类型可切除非小细胞肺癌中的临床结局

Clinical outcomes by type of surgery with perioperative durvalumab in patients with resectable non-small cell lung cancer.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-09-03

AEGEAN研究是一项双盲、安慰剂对照3期试验,评估围术期度伐利尤单抗联合新辅助化疗用于可切除非小细胞肺癌的疗效。按手术类型分层分析显示,度伐利尤单抗组病理完全缓解率和无事件生存获益在各手术亚组中总体维持,且≥3级手术并发症发生率低。

要点

  • 度伐利尤单抗组各手术类型病理完全缓解率均高于安慰剂组。
  • 无事件生存获益在肺叶切除等亚组中倾向度伐利尤单抗。
  • 各手术类型≥3级手术并发症发生率低。

核心结论

  • 围术期度伐利尤单抗联合新辅助化疗对比单纯新辅助化疗的临床获益在不同手术类型亚组中总体维持。

研究设计与样本

  • AEGEAN为双盲、安慰剂对照3期研究(NCT03800134),纳入初治可切除非小细胞肺癌(II-IIIB期[N2])成人患者。
  • 患者1:1随机接受新辅助化疗联合度伐利尤单抗或安慰剂,术后分别接受度伐利尤单抗或安慰剂辅助治疗。
  • 主要终点为改良意向治疗人群(排除EGFR/ALK异常)的病理完全缓解和无事件生存。

主要发现

  • 度伐利尤单抗组与安慰剂组分别有295例和302例患者接受手术(改良意向治疗人群)。
  • 肺叶切除比例分别为80.7% vs 73.2%,袖状切除/双肺叶切除为7.5% vs 12.3%,全肺切除为9.2% vs 9.6%。
  • 病理完全缓解率在度伐利尤单抗组 vs 安慰剂组:肺叶切除21.0% vs 5.4%,袖状切除/双肺叶切除36.4% vs 5.4%,全肺切除7.4% vs 3.4%。
  • 无事件生存风险比:肺叶切除HR 0.64(95%CI 0.46-0.88),袖状切除/双肺叶切除HR 0.59(95%CI 0.22-1.40),全肺切除HR 0.80(95%CI 0.36-1.74)。
  • ≥3级手术并发症发生率:肺叶切除4.2% vs 9.5%,袖状切除/双肺叶切除13.6% vs 5.4%,全肺切除14.8% vs 6.9%。

关键数值与推荐

  • 病理完全缓解率:肺叶切除21.0% vs 5.4%,袖状切除/双肺叶切除36.4% vs 5.4%,全肺切除7.4% vs 3.4%(度伐利尤单抗 vs 安慰剂)。
  • 无事件生存HR:肺叶切除0.64(95%CI 0.46-0.88),袖状切除/双肺叶切除0.59(95%CI 0.22-1.40),全肺切除0.80(95%CI 0.36-1.74)。
  • ≥3级手术并发症:肺叶切除4.2% vs 9.5%,袖状切除/双肺叶切除13.6% vs 5.4%,全肺切除14.8% vs 6.9%。

临床怎么用

  • 对于可切除非小细胞肺癌,围术期度伐利尤单抗联合新辅助化疗的获益在不同手术类型中总体一致,支持该方案用于适合手术的患者。

局限性

  • 袖状切除/双肺叶切除和全肺切除亚组样本量较小,无事件生存置信区间较宽。
  • 原文未报告各手术亚组的样本量及统计学检验细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess outcomes with perioperative durvalumab by type of surgery in patients with resectable non-small cell lung cancer (NSCLC) from the AEGEAN study. METHODS: AEGEAN is a double-blind, placebo-controlled phase 3 study (NCT03800134) of adults with treatment-naïve, resectable NSCLC (stage II-IIIB [N2]) who were randomized 1:1 to neoadjuvant chemotherapy plus durvalumab or placebo before surgery followed by adjuvant durvalumab or placebo. Primary end points were pathologic complete response and event-free survival in the modified intent-to-treat population, which excluded patients with documented EGFR/ALK aberrations. RESULTS: Of 295 and 302 patients in the durvalumab and placebo arms, respectively, who underwent surgery (modified intent-to-treat population), 80.7% versus 73.2% had lobectomy, 7.5% versus 12.3% had sleeve resection/bilobectomy, and 9.2% versus 9.6% had pneumonectomy. Rates of pathologic complete response were greater in the durvalumab versus placebo arm, regardless of surgery type (lobectomy: 21.0% vs 5.4%; sleeve resection/bilobectomy: 36.4% vs 5.4%; and pneumonectomy: 7.4% vs 3.4%). Event-free survival benefit favored the durvalumab versus placebo arm, regardless of surgery type (lobectomy: hazard ratio [HR], 0.64; 95% CI, 0.46-0.88; sleeve resection/bilobectomy: HR, 0.59; 95% CI, 0.22-1.40; and pneumonectomy: HR, 0.80; 95% CI, 0.36-1.74). The rates of maximum grade ≥3 surgical complications were low across both arms, regardless of surgery type (lobectomy: 4.2% vs 9.5%; sleeve resection/bilobectomy: 13.6% vs 5.4%; and pneumonectomy: 14.8% vs 6.9%). CONCLUSIONS: Clinical benefit with perioperative durvalumab plus neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone was generally maintained across the surgery subgroups.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Harpole D, Heymach JV, Reck M, et al. Clinical outcomes by type of surgery with perioperative durvalumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2026. PMID: 42692248. doi:10.1016/j.jtcvs.2026.04.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。